ANGEN Stock Overview
A biotechnology company, engages in the design, development, and manufacture of real-time PCR kits, nucleic acid extraction kits, and automated nucleic acid extraction instruments in Turkey. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Anatolia Tani ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret A.S. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₺13.41 |
| 52 Week High | ₺21.12 |
| 52 Week Low | ₺11.09 |
| Beta | -0.24 |
| 1 Month Change | 8.50% |
| 3 Month Change | -4.56% |
| 1 Year Change | -3.18% |
| 3 Year Change | -4.35% |
| 5 Year Change | n/a |
| Change since IPO | 8.41% |
Recent News & Updates
Recent updates
Shareholder Returns
| ANGEN | TR Biotechs | TR Market | |
|---|---|---|---|
| 7D | -8.0% | 0.2% | -1.6% |
| 1Y | -3.2% | 8.4% | 12.3% |
Return vs Industry: ANGEN underperformed the TR Biotechs industry which returned 7% over the past year.
Return vs Market: ANGEN underperformed the TR Market which returned 13.9% over the past year.
Price Volatility
| ANGEN volatility | |
|---|---|
| ANGEN Average Weekly Movement | 6.3% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in TR Market | 8.1% |
| 10% least volatile stocks in TR Market | 3.9% |
Stable Share Price: ANGEN has not had significant price volatility in the past 3 months compared to the TR market.
Volatility Over Time: ANGEN's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 235 | n/a | www.anatoliageneworks.com |
Anatolia Tani ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret A.S., a biotechnology company, engages in the design, development, and manufacture of real-time PCR kits, nucleic acid extraction kits, and automated nucleic acid extraction instruments in Turkey. It offers microbiology, genetic disorder, panel, sequencing, and food testing kits; and manual spin column and magnetic bead nucleic acid extraction kits, and automated NA extraction instrument kits. The company provides products for diseases, such as brucellosis, chlamydia trachomatis, cytomegalovirus, crimean-congo hemorrhagic fever, novel coronavirus (2019-NCoV)/SARS-CoV-2, epstein-barr virus, hepatitis B, hepatitis C, hepatitis D, herpes simplex virus, human immunodeficiency virus, human papillomavirus, JC and BK polyomaviruses, malaria, measles, meningitis, respiratory infection, parvovirus B19, torque teno virus, toxoplasmosis, tuberculosis, ureaplasma, and west nile virus diseases, as well as factor II, factor V leiden, and methylene-tetra-hydro-folate-reductase mutation diseases.
Anatolia Tani ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret A.S. Fundamentals Summary
| ANGEN fundamental statistics | |
|---|---|
| Market cap | ₺3.00b |
| Earnings (TTM) | -₺143.72m |
| Revenue (TTM) | ₺372.05m |
7.9x
P/S Ratio-20.5x
P/E RatioIs ANGEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ANGEN income statement (TTM) | |
|---|---|
| Revenue | ₺372.05m |
| Cost of Revenue | ₺100.43m |
| Gross Profit | ₺271.62m |
| Other Expenses | ₺415.35m |
| Earnings | -₺143.72m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.65 |
| Gross Margin | 73.01% |
| Net Profit Margin | -38.63% |
| Debt/Equity Ratio | 0.1% |
How did ANGEN perform over the long term?
See historical performance and comparisonDividends
4.4%
Current Dividend Yield-26%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/30 05:57 |
| End of Day Share Price | 2025/01/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Anatolia Tani ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret A.S. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|